Lizunov AV, Okunevich IV, Lebedev AA, Bychkov ER, Piotrovskiy LB, Shabanov PD. [Molecular mechanisms of the cytoprotector cramizol effect in the experimental dyslipidemia model].
BIOMEDITSINSKAIA KHIMIIA 2020;
66:326-331. [PMID:
32893822 DOI:
10.18097/pbmc20206604326]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The tested drug cramizol exhibits lipid-lowering and anti-atherogenic effects. Cramizol reduces blood cholesterol and triglycerides. It also increases HDL and reduces the atherogenic index in rats with the chronic dyslipidemia model induced by a hypercholesterol diet. Cramizol is effective as a hypolipidemic agent and its efficiency is comparable with the reference drug, phenofibrate. Cramizol increases expression of the ApoA1 and ApoC2 genes, and also reduces expression of the Scarb1 gene in rats with experimentally induced hyperlipidemia. These mechanisms could be the basis of its hypolipidemic and anti-atherogenic actions.
Collapse